Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05583617

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Conditions: Multiple Myeloma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 200

Sponsor: Hoffmann-La Roche

Location: Prince of Wales Hospital Randwick New South Wales

Summary

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Eligibility Criteria

Inclusion Criteria: * Diagnosed with MM per International Myeloma Working Group (IMWG) criteria * Eastern Cooperative Oncology Group Performance Status of 0, or 1, or 2 * Resolution of AEs from prior anti-cancer therapy to Grade \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05583617). StuddyBuddy aggregates publicly available trial information.